FDA warns against using terbutaline in preterm labor

Article

The United States Food and Drug Administration (FDA) has mandated a label change for terbutaline that warns against off-label use of the drug to prevent and treat preterm labor because of potentially fatal maternal heart problems.

The U.S. Food and Drug Administration (FDA) has mandated a label change for terbutaline that warns against off-label use of the drug to prevent and treat preterm labor because of potentially fatal maternal heart problems.

The new Boxed Warning and Contraindications alerts healthcare professionals not to give injectable terbutaline for prevention or prolonged treatment (ie, longer than 48 to 72 hours) of preterm labor and not to give oral terbutaline for prevention or treatment of preterm labor.

Based on a review of new data from postmarketing safety reports and the medical literature, FDA concluded that the risk of adverse events to the mother-including increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema, myocardial ischemia, and death-outweighs any potential obstetrical benefit of the drug. The label change is consistent with statements from the American College of Obstetricians and Gynecologists.

Terbutaline-which is approved to prevent bronchospasm accompanying asthma, bronchitis, and emphysema-is sometimes used off label to treat preterm labor and uterine hyperstimulation and, over longer periods, to prevent recurrent preterm labor.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.